Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Amortization of Deferred Charges (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Amortization of Deferred Charges for 8 consecutive years, with $612000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges rose 2.0% year-over-year to $612000.0, compared with a TTM value of $2.6 million through Dec 2025, up 26.81%, and an annual FY2025 reading of $2.6 million, up 26.81% over the prior year.
  • Amortization of Deferred Charges was $612000.0 for Q4 2025 at Zevra Therapeutics, down from $685000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $779000.0 in Q3 2024 and bottomed at $142000.0 in Q4 2021.
  • Average Amortization of Deferred Charges over 3 years is $503000.0, with a median of $606000.0 recorded in 2024.
  • The sharpest move saw Amortization of Deferred Charges tumbled 75.6% in 2021, then surged 177.41% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $142000.0 in 2021, then surged by 322.54% to $600000.0 in 2024, then rose by 2.0% to $612000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for ZVRA at $612000.0 in Q4 2025, $685000.0 in Q3 2025, and $689000.0 in Q2 2025.